Please assess the completion status of the following clinical trial:

Trial Title: AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~-Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period (at least 10 weeks after study intervention).~Exclusion Criteria:~* Known immunization or hypersensitivity to any botulinum neurotoxin serotype~* Any medical condition that may put the participant at increased risk with exposure to AGN-151586, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function~* Marked facial asymmetry, dermatochalasis, deep dermal scarring, excessively thick sebaceous skin, or the inability to substantially lessen facial lines even by physically spreading them apart, as determined by the investigator~* Any brow or eyelid ptosis, as determined by the investigator~* Infection or skin disorder at the injection sites~* History of facial nerve palsy~* Any uncontrolled systemic disease~* Anticipated need for treatment with botulinum neurotoxin of any serotype for any reason during the study (other than study intervention)~* Anticipated need for surgery or overnight hospitalization during the study~* Prior periorbital surgery, facial lift (full face or mid-face), thread lift, brow lift, or related procedures (eg, eyelid \[blepharoplasty\] and/or eyebrow surgery)~* Prior facial treatment with permanent soft tissue fillers, synthetic implantation (eg, Gore-Tex®), and/or autologous fat transplantation~* Current enrollment in an investigational drug or device study or participation in such a study within 30 days of Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received AGN-151586-matching placebo, intramuscular (IM) injections in the glabellar complex on Day 1 in Cohort 1.
- Cohort 1: AGN-151586 (Type: EXPERIMENTAL): Participants received AGN-151586 lowest dose, IM injections in the glabellar complex on Day 1.
- Cohort 2: Placebo (Type: PLACEBO_COMPARATOR): Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 2.
- Cohort 2: AGN-151586 (Type: EXPERIMENTAL): Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
- Cohort 3: Placebo (Type: PLACEBO_COMPARATOR): Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 3.
- Cohort 3: AGN-151586 (Type: EXPERIMENTAL): Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
- Cohort 4: Placebo (Type: PLACEBO_COMPARATOR): Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 4.
- Cohort 4: AGN-151586 (Type: EXPERIMENTAL): Participants received AGN-151586, IM injections in the glabellar complex on Day 1.
- Cohort 5: Placebo (Type: PLACEBO_COMPARATOR): Participants received AGN-151586-matching placebo, IM injections in the glabellar complex on Day 1 in Cohort 5.
- Cohort 5: AGN-151586 (Type: EXPERIMENTAL): Participants received AGN-151586 highest dose, IM injections in the glabellar complex on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete